Overview

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without bevacizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center
Treatments:
Bevacizumab
Capecitabine
Cetuximab
Oxaliplatin